USA - NASDAQ:LIVN - GB00BYMT0J19 - Common Stock
The current stock price of LIVN is 53.94 USD. In the past month the price decreased by -0.1%. In the past year, price increased by 1.84%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.21 | 218.95B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.58 | 193.16B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.51 | 146.46B | ||
| SYK | STRYKER CORP | 27.53 | 138.63B | ||
| MDT | MEDTRONIC PLC | 16.35 | 115.98B | ||
| IDXX | IDEXX LABORATORIES INC | 57.27 | 57.77B | ||
| BDX | BECTON DICKINSON AND CO | 12.55 | 51.32B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.74 | 49.40B | ||
| RMD | RESMED INC | 24.89 | 35.96B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.19 | 33.92B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.88 | 26.98B | ||
| DXCM | DEXCOM INC | 32.89 | 23.99B |
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
LIVANOVA PLC
20 Eastbourne Terrace
London W2 6LG GB
CEO: Damien McDonald
Employees: 2900
Phone: 442033250662
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
The current stock price of LIVN is 53.94 USD. The price increased by 2.59% in the last trading session.
LIVN does not pay a dividend.
LIVN has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The Revenue of LIVANOVA PLC (LIVN) is expected to grow by 8.58% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
LIVANOVA PLC (LIVN) has a market capitalization of 2.95B USD. This makes LIVN a Mid Cap stock.
LIVANOVA PLC (LIVN) will report earnings on 2025-11-05, before the market open.
ChartMill assigns a technical rating of 3 / 10 to LIVN. When comparing the yearly performance of all stocks, LIVN turns out to be only a medium performer in the overall market: it outperformed 58.65% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to LIVN. Both the profitability and the financial health of LIVN get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months LIVN reported a non-GAAP Earnings per Share(EPS) of 3.64. The EPS increased by 11.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.43% | ||
| ROE | -18.82% | ||
| Debt/Equity | 0.31 |
16 analysts have analysed LIVN and the average price target is 64.9 USD. This implies a price increase of 20.33% is expected in the next year compared to the current price of 53.94.
For the next year, analysts expect an EPS growth of 13.5% and a revenue growth 8.58% for LIVN